Leuven

• A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended
  2022-502393-16-00 5 2023-09-06 Moderately to Severely Active Ulcerative Colitis
• A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended
  2022-502647-35-00 4 2023-09-01 Non-alcoholic steatohepatitis
• A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patie … Ended
  2022-502828-42-00 4 2023-09-01 Idiopathic Pulmonary Fibrosis
• INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Stu … Ended
  2022-501661-47-00 4 2023-08-23 Myelofibrosis ; postlung transplant (BOS); chronic graft-versus-host d
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjectswith moderate to severe ulcerative colitis Ended
  2022-501263-41-00 4 2023-08-10 Ulcerative Colitis
• A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended
  2022-501097-19-00 4 2023-08-09 dermatomyositis
• MK-5684 Food Effect Study Ended
  2023-505521-14-00 3 2023-08-02 refractory metastatic prostate cancer
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• Safety and efficacy of NMD670 in ambulatory adult patients with Type 3 spinal muscular atrophy (SYNAPSE-SMA) Ended
  2024-516321-31-00 4 2023-07-07 Type 3 spinal muscular atrophy
• Phase 1 Study of PYX-106 in Solid Tumors Ended
  2023-509686-21-00 1 2023-07-05 Solid Tumors
• Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended
  2023-506046-24-00 4 2023-07-03 Ulcerative Colitis (UC)
• Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended
  2024-512646-42-00 4 2023-06-27 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• Outcome measures in SMA patients treated with Risdiplam. Ended
  2022-501760-17-00 5 2023-06-13 Spinal Muscular Atrophy (SMA)
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended
  2022-500101-41-00 6 2023-06-07 Type 2 Diabetes
• A study to test whether spesolimab helps people with skin disease called Netherton syndrome Ended
  2022-501104-10-00 10 2023-06-06 Netherton syndrome (NS)
• Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended
  2023-506268-15-00 5 2023-06-05 Chronic Rhinosinusitis (CRS) in Adults
• A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended
  2022-501420-20-00 5 2023-05-17 Severe hypertryglyceridemia
• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn … Ended
  2023-508777-91-00 10 2023-05-16 Moderately to Severely Active Crohn's Disease
• Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended
  2022-501585-22-00 5 2023-05-11 Atopic Dermatitis
• Safety, tolerability and pharmacokinetics of intra‐articular (IA) single ascending dose of 4P‐004 in patient with Kellgren and Lawrence grad … Ended
  2022-500271-31-00 3 2023-05-10 Knee osteoarthritis
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th … Ended
  2022-500121-33-01 5 2023-05-08 Anti-GBM antibody disease (Goodpasture disease)

Showing 961–984 of 1,135 trials